What are the latest funding news in the AI in drug discovery market? (October 2026)
Whether you're building or investing in the AI in drug discovery market, our report covers everything you need to know: the players, the money, and what's coming next.
AI in drug discovery funding remained highly active in September 2026, with investors backing companies across protein design, small-molecule discovery, target identification and preclinical prediction.
The 12 latest qualifying deals in our screening represented more than $1 billion of disclosed financing, even before counting rounds where only approximate or cumulative amounts were available.
Large growth rounds sat alongside early-stage bets, showing that investors are financing both clinically advanced AI-designed pipelines and new discovery platforms that are still validating their technology.
And if you want to better understand this new industry, you can download our pitch covering the AI in drug discovery market.
Insights
- More than $1 billion of disclosed capital went into these 12 AI in drug discovery financings, with Enveda, Anew Labs and Basecamp Research alone representing roughly three quarters of the clearly disclosed total.
- Three of the four largest rounds exceeded $100 million, suggesting that AI drug discovery investors are increasingly willing to fund companies beyond platform validation and into expensive therapeutic development.
- Protein and biologics design remained a major funding theme, with BigHat Biosciences and Basecamp Research using AI to design therapeutic sequences while combining computational models with proprietary biological data.
- Small-molecule discovery remained equally important, spanning natural-product chemistry at Enveda, allosteric drug discovery at NUTSHELL Therapeutics and GPCR-focused molecule design at Superluminal Medicines.
- Preclinical prediction is becoming a distinct investment category: Polyphron is building human tissue models, while Big Picture Bio is using a biological world model to predict effective cancer combinations.
- The market increasingly combines AI with physical experimentation rather than relying on software alone, as shown by BigHat's automated wet lab, Polyphron's Tissue Foundry and Ridge Biotechnologies' high-throughput experimental platform.
- Several funded companies are already approaching or entering human trials, which moves AI drug discovery closer to being judged on clinical results rather than only computational benchmarks or discovery speed.
- China remains relevant in the AI drug discovery funding landscape, with Anew Labs, NUTSHELL Therapeutics and AIPher demonstrating investor appetite for AI-native therapeutic platforms outside the United States and Europe.
- Investor strategies span very different maturity levels, from AIPher's Angel financing and Big Picture Bio's pre-seed round to Enveda's $311 million Series E and BigHat Biosciences' Series C.
Written by the New Market Pitch teamWe track new markets so founders and investors can move faster. About us
In our report covering the AI drug discovery market, you will always find fresh funding data, taken straight from our own verified funding database.
Summary table of the latest funding deals in the AI in drug discovery market as of October 2026
We define the AI in drug discovery market as revenue from AI-enabled software and related services that materially support the identification and design of therapeutic candidates before human trials.
We include AI used for target identification/validation, hit/lead generation, lead optimization, de novo design, repurposing, and preclinical prediction/assessment, including ADMET and toxicity prediction.
We exclude AI primarily used for clinical trial operations, regulatory submissions, manufacturing, pharmacovigilance, or commercial and enterprise analytics not directly tied to discovery and preclinical candidate selection.
| Name | When | Amount in $ | Round Type | Category |
|---|---|---|---|---|
| BigHat Biosciences | 24 September 2026 | $75M | Series C | AI biologics design & protein engineering |
| Enveda | 23 September 2026 | $311M | Series E | AI small-molecule & natural-product discovery |
| Basecamp Research | 23 September 2026 | $140M | Series C | AI biologics, peptide & gene-therapy design |
| Big Picture Bio | 18 September 2026 | ~$2M equity | Pre-seed | AI oncology combination design & preclinical prediction |
| Polyphron | 17 September 2026 | $20M | Seed | AI preclinical prediction & human tissue assessment |
| Anew Labs | 16 September 2026 | $290M | First external financing | AI molecular & biologic drug discovery |
| Mithrl | 15 September 2026 | $20M | Series A | AI target identification & scientific decision support |
| NUTSHELL Therapeutics | 15 September 2026 | Tens of millions | Series C1 | AI allosteric & small-molecule drug discovery |
| Ridge Biotechnologies | 9 September 2026 | ~$38M total capital raised | Upsized Seed | AI bioconjugate, enzyme & linker design |
| Moonwalk Biosciences | 8 September 2026 | $70M | Series B | AI target discovery & RNA therapeutics |
| Superluminal Medicines | 3 September 2026 | $60M | Series B | AI small-molecule & GPCR discovery |
| AIPher | 3 September 2026 | ~$14M | Angel | AI small-molecule & peptide discovery |
All the latest funding deals in the AI in drug discovery market as of October 2026
BigHat Biosciences raised $75 million in a Series C round in September 2026.
When was it?
BigHat Biosciences announced the financing on 24 September 2026.
Who are they?
BigHat Biosciences uses frontier AI and automated high-throughput experiments to design and optimize protein therapeutics such as antibodies and antibody-drug conjugates.
Geographical focus?
BigHat Biosciences is headquartered in San Mateo, California, and develops therapeutics and pharmaceutical partnerships for a global market.
Why do we include them in the AI in drug discovery market?
BigHat Biosciences belongs in AI drug discovery because AI-driven protein design and lead optimization sit at the center of its biologics discovery platform and therapeutic pipeline.
What is the company stage?
BigHat Biosciences is a clinical-stage growth company, with a wholly owned program already in Phase I and additional candidates in development.
How much did they raise?
BigHat Biosciences raised $75 million in this financing.
What round is it?
BigHat Biosciences completed a Series C round.
Why did they raise?
BigHat Biosciences raised the capital to advance its therapeutic pipeline and expand the automated data-generation and AI infrastructure supporting protein design.
In our research about AI drug discovery, we turn what is vague and complex into simple, useful visuals. Market maps like this one show you at a glance where every startup stands.
Enveda raised $311 million in a Series E round in September 2026.
When was it?
Enveda announced the financing on 23 September 2026.
Who are they?
Enveda uses AI to identify and characterize biologically active molecules found in plants and other natural sources and turn them into potential medicines.
Geographical focus?
Enveda is based in Boulder, Colorado, and develops medicines for global markets rather than one specific region.
Why do we include them in the AI in drug discovery market?
Enveda belongs in AI drug discovery because its platform performs hit discovery, candidate identification and prioritization from natural-product chemistry.
What is the company stage?
Enveda is a clinical-stage growth company with multiple AI-discovered programs already being tested in humans.
How much did they raise?
Enveda raised $311 million in this round.
What round is it?
Enveda completed a Series E round.
Why did they raise?
Enveda raised the money to advance existing clinical programs, move additional AI-discovered medicines into trials and continue scaling its discovery platform.
Basecamp Research raised $140 million in a Series C round in September 2026.
When was it?
Basecamp Research announced the financing on 23 September 2026.
Who are they?
Basecamp Research trains biological foundation models on large evolutionary datasets and uses them to design peptides, gene-editing systems and other therapeutic sequences.
Geographical focus?
Basecamp Research operates from London and Boston while building its biological dataset through partnerships across multiple continents.
Why do we include them in the AI in drug discovery market?
Basecamp Research belongs in AI drug discovery because its EDEN models perform de novo therapeutic design and optimization for biologic and genetic medicines.
What is the company stage?
Basecamp Research is at the preclinical growth stage and is advancing its first EDEN-designed therapeutic programs toward clinical development.
How much did they raise?
Basecamp Research raised $140 million in this financing.
What round is it?
Basecamp Research completed an oversubscribed Series C round.
Why did they raise?
Basecamp Research raised the money to train new EDEN models, advance AI-designed medicines toward the clinic and expand pharmaceutical partnerships.
Big Picture Bio secured about $2 million of equity financing in its September 2026 pre-seed round.
When was it?
Big Picture Bio publicly announced the financing package on 18 September 2026.
Who are they?
Big Picture Bio is building an AI world model that predicts how tumors, immune cells and their surroundings respond to drug combinations.
Geographical focus?
Big Picture Bio is based in London and initially focuses on oncology rather than a particular geographic market.
Why do we include them in the AI in drug discovery market?
Big Picture Bio belongs in AI drug discovery because its platform predicts resistance and designs therapeutic combinations before clinical development.
What is the company stage?
Big Picture Bio is at an early preclinical platform-validation stage and is moving predicted combinations from computational models into wet-lab testing.
How much did they raise?
Big Picture Bio raised about $2 million in equity, with additional non-dilutive funding bringing the broader package to roughly $3 million.
What round is it?
Big Picture Bio completed a pre-seed equity round alongside non-dilutive funding.
Why did they raise?
Big Picture Bio raised the financing to validate AI-designed cancer combinations in the laboratory and expand its platform and oncology programs.
In our market report about AI drug discovery, we always try to gather several sources and make estimates that make sense, so you can work with solid numbers.
Polyphron raised $20 million in a Seed round in September 2026.
When was it?
Polyphron announced the financing on 17 September 2026.
Who are they?
Polyphron combines AI with automated human tissue production to predict how potential drugs and biological interventions will behave in human-like tissues.
Geographical focus?
Polyphron is based in New York and targets drug developers broadly rather than focusing on one regional market.
Why do we include them in the AI in drug discovery market?
Polyphron belongs in AI drug discovery because its core product provides preclinical prediction and biological assessment of drug hypotheses before human trials.
What is the company stage?
Polyphron is at the Seed and MVP-to-scale stage, with initial tissue systems validated and manufacturing capacity now being expanded.
How much did they raise?
Polyphron raised $20 million in this round.
What round is it?
Polyphron completed a Seed financing.
Why did they raise?
Polyphron raised the capital to scale its tissue foundry, develop additional tissue types and improve its AI models for biological prediction.
Anew Labs secured $290 million in its first external financing in September 2026.
When was it?
Anew Labs' financing was reported on 16 September 2026.
Who are they?
Anew Labs develops AI models for protein structures, molecular dynamics, antibody design and molecular interactions and uses them to generate therapeutic programs.
Geographical focus?
Anew Labs originated in China, is headquartered in Shanghai and also operates internationally, including in the United States and Singapore.
Why do we include them in the AI in drug discovery market?
Anew Labs belongs in AI drug discovery because structure prediction, molecular design, antibody engineering and lead optimization are central to its therapeutic platform.
What is the company stage?
Anew Labs is a scaled preclinical company with multiple internally generated programs that remain predominantly before human testing.
How much did they raise?
Anew Labs raised $290 million in the financing.
What round is it?
Anew Labs completed its first external financing after becoming an independent company, without a consistently disclosed conventional series label.
Why did they raise?
Anew Labs raised the capital to expand its AI and experimental capabilities and advance internally generated drug candidates through discovery and preclinical development.
Mithrl raised $20 million in a Series A round in September 2026.
When was it?
Mithrl announced the financing on 15 September 2026.
Who are they?
Mithrl provides biopharma researchers with an AI scientific decision engine that helps identify targets, biomarkers, mechanisms and promising drug hypotheses.
Geographical focus?
Mithrl is based in San Francisco and serves biopharma organizations without a narrow regional focus.
Why do we include them in the AI in drug discovery market?
Mithrl belongs in AI drug discovery because its platform supports target identification, biological hypothesis generation and experimental prioritization during preclinical R&D.
What is the company stage?
Mithrl is at the PMF and early-growth stage, with deployments across pharmaceutical, biotechnology and genomics organizations.
How much did they raise?
Mithrl raised $20 million in this round.
What round is it?
Mithrl completed a Series A financing.
Why did they raise?
Mithrl raised the capital to develop the next generation of its biomedical world model and agentic decision platform and expand its biopharma deployments.
Our document detailing everything you need to know about AI drug discovery gets updated several times a month, so you always get the latest view of where things stand.
NUTSHELL Therapeutics raised tens of millions of dollars in a Series C1 round in September 2026.
When was it?
NUTSHELL Therapeutics announced the financing on 15 September 2026.
Who are they?
NUTSHELL Therapeutics combines AI and physics-based modeling to identify hidden allosteric protein pockets and design small molecules that act on them.
Geographical focus?
NUTSHELL Therapeutics is based in China and is developing its drug pipeline and collaborations for international markets.
Why do we include them in the AI in drug discovery market?
NUTSHELL Therapeutics belongs in AI drug discovery because its platform directly supports target-pocket identification, ligand generation and small-molecule optimization.
What is the company stage?
NUTSHELL Therapeutics is a clinical-stage growth company with programs generated by its discovery platform already progressing through development.
How much did they raise?
NUTSHELL Therapeutics disclosed a financing in the tens of millions of US dollars but did not publish a precise amount.
What round is it?
NUTSHELL Therapeutics completed a Series C1 round.
Why did they raise?
NUTSHELL Therapeutics raised the financing to scale its AI and physics-based allosteric discovery platform and advance its small-molecule pipeline.
Ridge Biotechnologies expanded its Seed financing to about $38 million of total capital raised in September 2026.
When was it?
Ridge Biotechnologies announced the additional investment on 9 September 2026.
Who are they?
Ridge Biotechnologies trains machine-learning models on experimental data to design enzymes and conditionally activated linkers for precision bioconjugate medicines.
Geographical focus?
Ridge Biotechnologies is based in Palo Alto, California, and works with biotechnology and pharmaceutical partners broadly.
Why do we include them in the AI in drug discovery market?
Ridge Biotechnologies belongs in AI drug discovery because its machine-learning platform performs therapeutic component design and lead optimization before clinical development.
What is the company stage?
Ridge Biotechnologies is at an early-growth and PMF stage, with commercial partnerships and internal preclinical therapeutic programs.
How much did they raise?
Ridge Biotechnologies said the expanded Seed financing brought total capital raised to approximately $38 million, but it did not disclose the fresh September tranche separately.
What round is it?
Ridge Biotechnologies described the financing as an upsized Seed round.
Why did they raise?
Ridge Biotechnologies raised additional capital to support partnerships, scale data generation and machine learning, broaden its enzyme and linker portfolio and advance internal programs.
In our report covering the AI drug discovery market, we look at what the winners do differently, so you can learn from the best instead of guessing.
Moonwalk Biosciences raised $70 million in a Series B round in September 2026.
When was it?
Moonwalk Biosciences announced the financing on 8 September 2026.
Who are they?
Moonwalk Biosciences combines genetics, epigenomics, multi-omics and AI to discover therapeutic targets and develop tissue-selective RNA-interference medicines.
Geographical focus?
Moonwalk Biosciences operates from South San Francisco and San Diego and focuses on obesity and cardiometabolic diseases rather than one geographic market.
Why do we include them in the AI in drug discovery market?
Moonwalk Biosciences belongs in AI drug discovery because its platform uses AI for therapeutic target discovery and preclinical candidate design.
What is the company stage?
Moonwalk Biosciences is at the late-preclinical and IND-enabling stage, with its lead program being prepared for first-in-human development.
How much did they raise?
Moonwalk Biosciences raised $70 million in this financing.
What round is it?
Moonwalk Biosciences completed a Series B round.
Why did they raise?
Moonwalk Biosciences raised the capital to complete IND-enabling work, advance its lead obesity program and expand its tissue-targeted RNAi pipeline.
Superluminal Medicines raised $60 million in a Series B round in September 2026.
When was it?
Superluminal Medicines announced the financing on 3 September 2026.
Who are they?
Superluminal Medicines combines AI, machine learning, protein-dynamics modeling and structural biology to discover and optimize small molecules against difficult GPCR targets.
Geographical focus?
Superluminal Medicines is based in Boston and focuses on endocrine and cardiometabolic diseases rather than one geographic market.
Why do we include them in the AI in drug discovery market?
Superluminal Medicines belongs in AI drug discovery because its Hyperloop platform performs structure-based hit discovery and lead optimization for therapeutic molecules.
What is the company stage?
Superluminal Medicines is at the late-preclinical stage and is transitioning toward clinical development with its lead obesity program.
How much did they raise?
Superluminal Medicines raised $60 million in this financing.
What round is it?
Superluminal Medicines completed an oversubscribed Series B round.
Why did they raise?
Superluminal Medicines raised the capital to move its lead program into Phase I, advance additional candidates and expand its GPCR-focused discovery platform.
AIPher raised about $14 million in an Angel round in September 2026.
When was it?
AIPher announced the financing on 3 September 2026.
Who are they?
AIPher develops AI foundation models and agent systems for target discovery, molecule generation, candidate optimization and experimental drug discovery.
Geographical focus?
AIPher is based in Beijing and initially works closely with Chinese pharmaceutical and biotechnology companies, although its technology can support global drug discovery.
Why do we include them in the AI in drug discovery market?
AIPher belongs in AI drug discovery because its core platform directly supports target discovery, hit generation, molecular design and lead optimization.
What is the company stage?
AIPher is at a very early preclinical stage and is advancing its first proprietary and partnered programs toward candidate selection.
How much did they raise?
AIPher raised about RMB100 million, equivalent to roughly $14 million at contemporaneous exchange rates.
What round is it?
AIPher completed an Angel financing round.
Why did they raise?
AIPher raised the capital to develop its DrugCLIP and PharmAgents systems, strengthen its computational and experimental loop and advance early drug programs.
In our research about AI drug discovery, we don't want to repeat what boring consulting reports say. Instead, we show you the real and latest market signals that matter.
Written by the New Market Pitch teamWe track new markets so founders and investors can move faster. About us